Well, let's assume that they were filling the pipeline a bit. Nevertheless, very powerful launch. My surveillance of the uc support blog suggests that many patients are asking their physicians for Uceris before, in some cases, the physicians are even aware of it. As long as we're pipedreaming, I'll guess $80m in 2013 sales.
Nah, I meant to say $60 mil in 2013. I don't care. The really significant fact is that this is being used as both a post-flare and maintenance therapy. As Gerry said, the gastroenterologists know the drug and the technology, and are comfortable with it. Little education needed = quick adoption.